Drug intelligence / Profile preview

olmesartan medoxomil + metoprolol succinate

Development stage: Unknown
Lead developer: Mitoch Pharma
Modality: Small Molecules
Administration: Oral

Overview

Olmitoch MT is a cardiovascular combination tablet marketed by Mitoch Pharma in India, containing olmesartan medoxomil (20 mg) and metoprolol succinate extended-release (50 mg). Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that targets the AT1 receptor, promoting vasodilation and reducing blood pressure by blocking the vasoconstrictive effects of angiotensin II. Metoprolol succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate and cardiac output. Together, these agents provide a synergistic approach to managing hypertension and other cardiovascular conditions.

Brand names: Olmitoch MTOlmitoch MT 20/50
Other names: Olmesartan Medoxomil and Metoprolol Succinate Extended-Release Tablets

Targets

ADRB1 (β1)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on olmesartan medoxomil + metoprolol succinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olmesartan medoxomil + metoprolol succinate.

Explore the full profile